Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration (FDA) has notified health care professionals of serious adverse events including liver failure and death linked to a topical NSAID prescribed for the treatment of osteoarthritis. Postmarketing reports indicate that cases of drug-induced hepatotoxicity have been reported in the first month but can occur at any time during treatment with Voltaren Gel (diclofenac sodium topical gel) 1 %. Postmarketing surveillance has reported cases of severe hepatic reactions including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure. Some of these reported cases resulted in fatalities or liver transplantation.

Read the rest of this entry »